- Home
- FOA vs IMMP Comparison
FOA vs IMMP Comparison
Compare FOA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- IMMP
- Stock Information
- Founded
- FOA 2013
- IMMP 1987
- Country
- FOA United States
- IMMP Australia
- Employees
- FOA N/A
- IMMP N/A
- Industry
- FOA Finance Companies
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- IMMP Health Care
- Exchange
- FOA Nasdaq
- IMMP Nasdaq
- Market Cap
- FOA 272.8M
- IMMP 256.1M
- IPO Year
- FOA N/A
- IMMP N/A
- Fundamental
- Price
- FOA $23.64
- IMMP $1.72
- Analyst Decision
- FOA Buy
- IMMP Buy
- Analyst Count
- FOA 2
- IMMP 1
- Target Price
- FOA $27.50
- IMMP $7.00
- AVG Volume (30 Days)
- FOA 91.6K
- IMMP 139.4K
- Earning Date
- FOA 11-04-2025
- IMMP 02-22-2026
- Dividend Yield
- FOA N/A
- IMMP N/A
- EPS Growth
- FOA N/A
- IMMP N/A
- EPS
- FOA N/A
- IMMP N/A
- Revenue
- FOA $318,296,000.00
- IMMP $3,306,742.00
- Revenue This Year
- FOA $21.21
- IMMP N/A
- Revenue Next Year
- FOA $10.95
- IMMP N/A
- P/E Ratio
- FOA N/A
- IMMP N/A
- Revenue Growth
- FOA N/A
- IMMP 31.28
- 52 Week Low
- FOA $16.58
- IMMP $1.32
- 52 Week High
- FOA $32.40
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- FOA 55.78
- IMMP 38.74
- Support Level
- FOA $22.43
- IMMP $1.78
- Resistance Level
- FOA $23.26
- IMMP $1.95
- Average True Range (ATR)
- FOA 0.81
- IMMP 0.09
- MACD
- FOA 0.14
- IMMP -0.01
- Stochastic Oscillator
- FOA 71.60
- IMMP 23.33
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.